{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-071386","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.695273+00:00","generated_at":"2026-05-21T08:39:33.412212+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"confidence":"high","headline":"Clearside Biomedical Q1 net loss narrows to $8.2M; FDA agrees on Phase 3 plan for CLS-AX in wet AMD","bullets":["Net loss $8.2M ($0.11/sh) vs $11.8M ($0.17) YoY; license revenue $2.3M (up from $0.2M) on Arctic Vision milestone.","Successful End-of-Phase 2 FDA meeting; alignment on Phase 3 design for CLS-AX targeting 3-6 month flexible dosing in wet AMD.","Partner Arctic Vision: ARCATUS approved in Australia and Singapore; NDA accepted for review in China for uveitic macular edema.","Partner BioCryst authorized to start clinical trial for avoralstat in DME using Clearside's SCS Microinjector; initial data expected in 2025.","Cash $13.6M at March 31, expected to fund operations into Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-071386","json":"https://secwatch.observer/filing/0000950170-25-071386.json","markdown":"https://secwatch.observer/filing/0000950170-25-071386.md","text":"https://secwatch.observer/filing/0000950170-25-071386.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017025071386/0000950170-25-071386-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017025071386/clsd-20250514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T08:39:33.412212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}